Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board [Yahoo! Finance]
Adagene Inc. - ADS, each representing 1.25 ordinary shares (ADAG)
Company Research
Source: Yahoo! Finance
SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development at USC Norris. He is also Professor of Medicine and Preventive Medicine and the J Terrence Lanni Chair for Cancer Research in the Division of Medical Oncology with Keck School of Medicine of USC. “Microsatellite stable (MSS) colorectal cancer (CRC) remains one of the cold tumors where effective immunotherapy still remains elusive and I believe anti-CTLA-4 therapy should be part of the solution,” said Dr. Lenz. “By enabling CTLA-mediated
Show less
Read more
Impact Snapshot
Event Time:
ADAG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAG alerts
High impacting Adagene Inc. - ADS, each representing 1.25 ordinary shares news events
Weekly update
A roundup of the hottest topics
ADAG
News
- Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Adagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target SolutionsPR Newswire
- Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardGlobeNewswire
- Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 [Financial Post (Toronto, Ontario, Canada)]Financial Post
ADAG
Sec Filings
- 3/29/24 - Form 6-K
- 3/29/24 - Form 424B5
- 3/29/24 - Form 20-F
- ADAG's page on the SEC website